Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Analyzing REGENXBIO (NASDAQ:RGNX) and Dogwood Therapeutics (NASDAQ:DWTX)
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% – Time to Buy?
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Expands By 61.2%
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
Dogwood Therapeutics, Inc. - Special Call
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
Dogwood Therapeutics Announces First Quarter 2025 Financial Results
Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024